| P2093 | author name string | J J Gilmartin | |
| | Paul Donnellan | |
| | Dympna Waldron | |
| | Maccon Keane | |
| | Eileen Mannion | |
| P2860 | cites work | Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation | Q70356145 |
| | Evidence for a role of EGF receptor in the progression of human lung carcinoma | Q70470178 |
| | Quality of life in cancer patients. Who measures what? | Q70696491 |
| | Quality of Life in Clinical Cancer Trials. Introduction | Q71376207 |
| | Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group | Q71791969 |
| | Polychemotherapy in advanced non small cell lung cancer: a meta-analysis | Q72223329 |
| | A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis | Q72839745 |
| | Non-small-cell lung cancer--stalemate or progress? | Q73172933 |
| | Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin | Q73339722 |
| | Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results | Q73620250 |
| | Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy | Q77994599 |
| | The biology of VEGF and its receptors | Q27860704 |
| | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 |
| | The hospital anxiety and depression scale | Q27860968 |
| | Cancer statistics, 2001 | Q28189339 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Erlotinib in previously treated non-small-cell lung cancer | Q29547546 |
| | Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 |
| | Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 |
| | Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer | Q29620038 |
| | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 |
| | Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer | Q33329807 |
| | Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project | Q33330488 |
| | Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial | Q33344019 |
| | Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial | Q33344679 |
| | Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer | Q33364148 |
| | Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. | Q33364348 |
| | Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group | Q33369265 |
| | Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel | Q33369267 |
| | Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial | Q33374797 |
| | Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer | Q33384455 |
| | Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis | Q33488295 |
| | Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer | Q33498591 |
| | Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study | Q33499376 |
| | Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group | Q33502766 |
| | Gemcitabine: single-agent and combination therapy in non-small cell lung cancer | Q33679980 |
| | Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews | Q33837105 |
| | Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature | Q34292388 |
| | A critical appraisal of the quality of quality-of-life measurements | Q34309154 |
| | A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. | Q34435385 |
| | Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 |
| | Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 |
| | Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer | Q34596877 |
| | Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life | Q35536245 |
| | Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist | Q35982281 |
| | Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas | Q36291695 |
| | Who should measure quality of life, the doctor or the patient? | Q36466485 |
| | Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. | Q36612331 |
| | Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer | Q36642218 |
| | A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. | Q36695252 |
| | Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. | Q38553138 |
| | The problem of quality of life in medicine | Q39227551 |
| | Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial | Q39349621 |
| | Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin | Q39421412 |
| | First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale | Q39929767 |
| | Measuring and analysing quality of life in cancer clinical trials: a review. | Q40173611 |
| | Health status and quality of life: which matters to the patient? | Q40390405 |
| | Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer | Q40649739 |
| | Lessons learned from measuring health-related quality of life in oncology | Q40720847 |
| | New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions | Q40857308 |
| | Quality of life issues in palliative medicine | Q40875539 |
| | Comparison of instruments for measuring quality of life in patients with lung cancer. | Q40975925 |
| | Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? | Q41065393 |
| | Quality of life in cancer patients--an hypothesis | Q41561511 |
| | Phase I trial of weekly paclitaxel in advanced lung cancer | Q42545457 |
| | Quality of life assessment in clinical cancer research | Q42590178 |
| | Partnership with patients | Q43150140 |
| | Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial | Q43620879 |
| | Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial | Q43658480 |
| | Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group | Q43707358 |
| | Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine | Q43791685 |
| | Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial | Q43878521 |
| | Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial | Q43998644 |
| | Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T | Q44499454 |
| | Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life | Q44545383 |
| | Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. | Q44633976 |
| | Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group | Q44726998 |
| | Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial | Q44738919 |
| | Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group | Q44936612 |
| | Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial | Q45256412 |
| | Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status | Q45267156 |
| | Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial | Q45280581 |
| | Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer | Q46201985 |
| | Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer | Q46681061 |
| | Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. | Q47293786 |
| | Estimates of the worldwide incidence of eighteen major cancers in 1985. | Q50609607 |
| | A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. | Q50976951 |
| | Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study G | Q51093065 |
| | Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. | Q51260397 |
| | Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. | Q52857339 |
| | Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). | Q52885337 |
| | Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. | Q52895249 |
| | Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. | Q53450116 |
| | Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. | Q53511212 |
| | Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. | Q53517685 |
| | Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. | Q53518274 |
| | Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. | Q53521886 |
| | A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). | Q53527972 |
| | Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. | Q53531493 |
| | Quality-of-life measurement in advanced cancer: assessing the individual. | Q53538439 |
| | Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument | Q53642823 |
| | The Sickness Impact Profile: Development and Final Revision of a Health Status Measure | Q55063071 |
| | The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials | Q56562737 |
| | Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer | Q60685440 |
| | Assessing the quality of life of patients in cancer clinical trials: Common problems and common sense solutions | Q68031468 |
| | Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study | Q69325947 |
| | Advance directives for medical care--a case for greater use | Q70111595 |
| P433 | issue | 5 | |
| P921 | main subject | lung cancer | Q47912 |
| | chemotherapy | Q974135 |
| P304 | page(s) | 1417-1428 | |
| P577 | publication date | 2014-02-22 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Effect of chemotherapy on quality of life in patients with non-small cell lung cancer | |
| P478 | volume | 22 | |